Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 541 to 550 of 875

TitleReference numberPublishedLast updated
Eltrombopag for treating chronic immune thrombocytopeniaTA293
Romiplostim for the treatment of chronic immune thrombocytopeniaTA221
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanomaTA544
Cabozantinib for untreated advanced renal cell carcinomaTA542
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA543
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemiaTA541
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumoursTA539
Dinutuximab beta for treating neuroblastomaTA538
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodineTA535
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536

Results per page

  1. 10
  2. 25
  3. 50
  4. All